2025-09-11 - Analysis Report
Okay, here's a report analyzing Johnson & Johnson (JNJ) based on the provided data.

**Report: Johnson & Johnson (JNJ) Analysis**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** JNJ
*   **Company Overview:** Johnson & Johnson is a global healthcare company engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field.
*   **JNJ Cumulative Return:** 29.81%
*   **VOO Cumulative Return:** 39.61%
*   **Relative Divergence:** -9.8% (Current: -71.1, Relative Divergence: 11.6)
    *   The relative divergence indicates that JNJ's performance is lagging behind the S&P 500. The current value of -71.1 is significantly below the benchmark, placing it in the lower end of its historical range. The relative divergence of 11.6 suggests JNJ is performing near the bottom of its historical performance relative to the S&P 500.

**Alpha/Beta Analysis**

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
| :----------- | :------ | :------ | :------ | :----- | :----- |
| 2015-2017  | 28.0%  | 56.1%  | 28.0%  | 1.0    | 334.3  |
| 2016-2018  | 8.0%  | 56.6%  | 8.0%  | 1.0    | 308.7  |
| 2017-2019  | 18.0%  | 56.6%  | 18.0%  | 1.0    | 349.0  |
| 2018-2020  | 12.0%  | 59.2%  | 12.0%  | 1.0    | 376.5  |
| 2019-2021  | 32.0%  | 59.6%  | 31.0%  | 0.0    | 409.3  |
| 2020-2022  | 7.0%  | 61.4%  | 18.0%  | -0.0   | 422.6  |
| 2021-2023  | -15.0% | 61.4%  | -25.0% | -0.0   | 375.0  |
| 2022-2024  | -35.0% | 61.4%  | -65.0% | -0.0   | 346.0  |
| 2023-2025  | 3.0%  | 70.1%  | -43.0% | -0.0   | 423.4  |

*   **Analysis:**
    *   The CAGR (Compound Annual Growth Rate) shows fluctuating performance over different periods.
    *   MDD (Maximum Drawdown) remains relatively high, indicating significant potential for loss.
    *   Alpha has been negative in recent years, suggesting underperformance compared to the benchmark.
    *   Beta is close to 0, indicating that JNJ's price is not highly correlated with the overall market.

**2. Recent Price Action**

*   **Current Price:** 176.9600067138672
*   **Last Market Data:** Price: 175.79, Previous Close: 176.96, Change: -0.66
*   **5-day Moving Average:** 178.056
*   **20-day Moving Average:** 177.0605
*   **60-day Moving Average:** 166.2703

*   **Analysis:**
    *   The stock price is slightly below the 5-day and 20-day moving averages but above the 60-day moving average.  This suggests some short-term downward pressure but a longer-term upward trend.
    *   The recent price change of -0.66 indicates a slight downward movement.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3261 (Low Risk)
*   **RSI:** 46.34 (Neutral)
*   **PPO:** -0.33 (Bearish)
*   **Hybrid Signal:** cash_67%_Sell 4.0% of holdings (13 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Divergence Change:** 1.9 (+, Short-term Increase)
*   **Expected Return (%):** -245.7%

*   **Analysis:**
    *   The Market Risk Indicator is in the Low Risk zone.
    *   The RSI is neutral, suggesting neither overbought nor oversold conditions.
    *   The PPO is negative, indicating a bearish trend.
    *   The hybrid signal suggests a cautious approach, recommending increasing cash holdings and selling a small portion of shares.
    *   The recent increase in relative divergence suggests a short-term improvement in JNJ's performance compared to the S&P 500, but the longer term expected return is significantly negative, indicating potential underperformance over a 2+ year investment horizon.

**4. Recent News & Significant Events**

*   **Key Headlines:**
    *   Trump’s potential impact on prescription drug ads.
    *   FDA approval for Johnson & Johnson's bladder cancer drug (Inlexzoh).
    *   Analyst focus on large drug stocks, including JNJ.
    *   J&J's strengthened pipeline momentum with FDA approval.

*   **Impact:** The news surrounding the FDA approval for the bladder cancer drug is a positive catalyst. However, the potential regulatory changes regarding prescription drug ads could create uncertainty.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.25)
*   **Target Price:** Average: $177.47, High: $200.00, Low: $155.00
*   **Recent Rating Changes:** Not specified

*   **Analysis:** The analyst consensus is generally positive, with a "Buy" rating and an average target price slightly above the current price.

**5. Recent Earnings Analysis**

| 날짜         | EPS   | 매출       |
| :----------- | :---- | :--------- |
| 2025-07-24  | 2.30  | 23.74 B$   |
| 2025-04-23  | 4.57  | 21.89 B$   |
| 2024-10-23  | 1.12  | 22.47 B$   |
| 2024-07-25  | 1.95  | 22.45 B$   |
| 2025-07-24  | 1.95  | 22.45 B$   |

*   **Analysis:**  Earnings per share (EPS) and revenue have fluctuated. The most recent quarter (2025-07-24) shows higher revenue but a lower EPS compared to the previous quarter.

**6. Financial Information**

**Revenue and Profitability**

| Quarter      | Revenue   | Profit Margin |
| :----------- | :-------- | :------------ |
| 2025-06-30  | $23.74B  | 67.87%       |
| 2025-03-31  | $21.89B  | 66.40%       |
| 2024-12-31  | $22.52B  | 68.35%       |
| 2024-09-30  | $22.47B  | 69.01%       |
| 2024-06-30  | $22.45B  | 69.40%       |

**Capital and Profitability**

| Quarter      | Equity    | ROE      |
| :----------- | :-------- | :------- |
| 2025-06-30  | $78.47B  | 7.06%    |
| 2025-03-31  | $78.11B  | 14.08%   |
| 2024-12-31  | $71.49B  | 4.80%    |
| 2024-09-30  | $70.16B  | 3.84%    |
| 2024-06-30  | $71.54B  | 6.55%    |

*   **Analysis:**
    *   Revenue shows an increase in the latest quarter.
    *   Profit margins are consistently high, indicating strong profitability.
    *   Equity has been increasing.
    *   Return on Equity (ROE) has fluctuated, with a significant increase in the first quarter of 2025.

**7. Overall Assessment**

Johnson & Johnson (JNJ) presents a mixed picture.

*   **Strengths:**
    *   Stable company with a diversified healthcare portfolio.
    *   Recent FDA approval is a positive catalyst.
    *   High and consistent profit margins.
    *   Low Market Risk Indicator.
    *   Positive analyst consensus.

*   **Weaknesses:**
    *   Underperformance compared to the S&P 500 (negative alpha).
    *   Fluctuating EPS and ROE.
    *   Bearish PPO indicator.
    *   Cautious hybrid signal.
    *   Significantly negative expected return over the long term.
    *   Potential regulatory headwinds regarding drug advertising.

*   **Recommendation:**  While JNJ is a large, stable company, the data suggests caution. The underperformance relative to the S&P 500, negative long-term expected return, and cautious hybrid signal warrant a conservative approach. The positive analyst consensus and recent FDA approval provide some offsetting factors, but a more thorough analysis of the reasons for the negative expected return is advisable before making a long-term investment decision. The recommendation would lean towards holding existing positions or initiating small, carefully considered positions.
